Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer

Tanguy I. Seiwert, MD
Published: Friday, Dec 23, 2016



Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

Head and neck cancer is generally curable; however, once it becomes recurrent or metastatic, the prognosis becomes very poor, Seiwert explains. Available treatments such as cetuximab (Erbitux) and chemotherapy regimens do not typically lead to survival benefits for patients. The field appeared to be very dismal, he says, until the approvals of the PD-1 inhibitors. These agents have a response rate of 13% to 20%, but they have a major impact on overall survival (OS). Currently, the 1-year OS rate with these agents is approximately 40%, which is unreached with other treatments.

These agents influence OS in a very significant way, while progression-free survival and response rate are not good markers of benefit, he adds.
 


Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

Head and neck cancer is generally curable; however, once it becomes recurrent or metastatic, the prognosis becomes very poor, Seiwert explains. Available treatments such as cetuximab (Erbitux) and chemotherapy regimens do not typically lead to survival benefits for patients. The field appeared to be very dismal, he says, until the approvals of the PD-1 inhibitors. These agents have a response rate of 13% to 20%, but they have a major impact on overall survival (OS). Currently, the 1-year OS rate with these agents is approximately 40%, which is unreached with other treatments.

These agents influence OS in a very significant way, while progression-free survival and response rate are not good markers of benefit, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x